SITC - Society for Immunotherapy and Cancer
October 30, 2025
SITC - Society for Immunotherapy and Cancer 2025
Type: Conference
Dates: November 5th-9th, 2025
Location:
National Harbor, MD
Four decades ago, promising scientific breakthroughs in recombinant DNA technology, monoclonal antibody technology and tumor immunology were just evolving as budding foundations of cancer research. Now, SITC is at the forefront of immuno-oncology, helping luminaries in the field and young investigators connect with resources and expertise in biotech startups, academia, government and established pharmaceutical firms.
Authors: Chenoweth, A. M., et al. (2025). An Fc-engineered glycomodified antibody supports proinflammatory activation of immune effector cells and restricts progression of breast cancer. Cancer Research. Journal: Cancer Research
Authors: Rumyantsev, A., et al. (2025). Safety and immunogenicity of UB-612 heterologous booster: A pivotal Phase 3 study. eClinicalMedicine, The Lancet. Journal: The Lancet
Authors: Stefanutti E, Ramani R, Whitener B, Dang H, Bélanger S, Somasundaram L, Cortina K, De Marco A, Tam T, Chai Q, Cameroni E, Gupta R, Schmid MA, Miller JL, Zumsteg AB, Purcell LA, Drewry LL. 0. Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies. Microbiol Spectr 0:e00863-25. Journal: Microbiology Spectrum
Antibody Engineering & Therapeutics 2025
The Fc-Mediated Effector Function Summit
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1). Journal: mAbs
Authors: Osborn, G., López-Abente, J., Adams, R. et al.
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
